Malaria has been with us long before the dawn of civilization. It shaped the destiny of peoples, nations, and colonies, influencing the outcomes of ancient military campaigns. Malaria is suspected to have caused the death of Alaric, king of the Visigoths, after he sacked ancient Rome and that of the 18th-century English poet Lord Byron. The war against malaria has been long and hard. Looking back 20 years since my graduate studies in Nigeria, many smaller battles have been won in this war. Efforts such as the Roll Back Malaria initiative, the Multilateral Initiative on Malaria, the Global Fund and the WHO malaria programme inter alia led to improvements in malaria control, treatment recommendations and policies, coordinated purposeful research, new tools and strategies, and a heightened overall awareness about the disease. An arrest in the rise of malaria deaths has now been followed by a global net decline for the first time in 40 years! Yet more challenges remain before we can declare this ancient scourge eliminated globally as a public health threat. We must continue to pursue new medicines and approaches to kill the parasite, control mosquito vectors, limit disease transmission, and improve the immunity of people most susceptible to malaria. Until we identify and overcome barriers that prevent delivery of these tools, interventions, and policies, there are still many rivers to cross. Is there a more despised organism than the mosquito? The consensus seems to be that a world without them would be a better and healthier place, ridden of all diseases that they transmit. In the attempts to stop Anopheles mosquitoes from transmitting malaria, we use powerful insecticides aimed at killing female mosquitoes while they try to feed on our blood. But their formidable resilience pushes us towards rethinking this strategy; malaria eradication will need alternative, complementary approaches to target parasite transmission in more subtle ways than simply killing the mosquito. There are reasons for optimism as progress is happening at an exceptional pace. A new generation of gene editing tools such CRISPR/Cas have the capacity to manipulate genomes with high precision and effectiveness. We could potentially modify entire Anopheles populations with desired genetic traits, selectively killing the malaria parasite rather than the mosquito host. These so called ''gene drive'' systems transcend geographical boundaries and are potentially so potent that their ecological and environmental consequences will need to be carefully evaluated. The wealth of genomic information recently generated for numerous Anopheles species will enable identification of key biological pathways that can be targeted by compounds that specifically hinder Plasmodium parasite development. The next decade will be crucial for the generation of tailored, environmentally conscious methods that can block disease transmission without imposing unbearable pressures to mosquito populations.
Basic Research for New Tools
Chetan E. Chitnis
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Intensive malaria control programs have greatly reduced both malaria incidence and transmission in many endemic regions. Expanding coverage of available tools alone, however, is unlikely to eliminate malaria. In areas with residual transmission, relaxing control efforts will inevitably lead to a rapid rebound of malaria. There is an urgent need to discover novel strategies and tools against the parasite or vector that synergize to reduce the basic reproduction rate of malaria parasites to less than 1 (R o < 1) by simultaneously blocking growth and transmission at multiple points in the parasite life cycle. Such novel tools require breakthroughs in our understanding of the biology of parasite life stages. Whole-genome approaches could identify metabolic, biosynthesis, or signaling pathways shared across parasite stages that could then be targeted with inhibitors to block both development in the human host and transmission to the mosquito. Of the two predominant human malaria parasite species, P. falciparum and P. vivax, the latter is more difficult to eliminate due to its unique biology, including the poorly understood latent hypnozoite stage. Relapsing blood stage infections from hypnozoites contribute significantly to ongoing P. vivax burden and transmission in endemic regions. Understanding the biology of this stage will be key for P. vivax detection and elimination. Increased support for basic research into the biology of malaria parasites is therefore pivotal for the path towards achieving malaria elimination. Almost 20 years ago, at a time when one child died every 12 seconds of malaria, the African Malaria Initiative voiced a cry of help to the global scientific community. Since then, swift action led to measures to control the death toll. Yet, the ultimate goal of malaria eradication remains unfulfilled; one child still dies every minute. We are at a critical turning point, where utility of current approaches have peaked and the need is urgent to invest and invent new tools. However, this cannot be a shot in the dark-a true understanding of the fundamental biology of the malaria parasite needs to be achieved. A paradigmatic example is the liver stage of infection, critical for parasite establishment in the mammalian host but still underexplored biology-wise. In the hepatocyte, the parasite reaches its highest replication rate, generating tens of thousands of new parasites in days. In certain Plasmodium species, a proportion of the parasites that reach the liver can survive for extended periods of times as hypnozoites until reactivation. What drives these distinct replicative behaviors still eludes us. Humans and other vertebrate hosts have lived with Plasmodium parasites for eons, developing the ability to sense and integrate signals from one another. This ability, transversal to all stages of the malaria parasite's life cycle, may well be at the basis of the success of its lifestyle. Understanding it will certainly impact on the success of malaria eradication.
Parasite ENCODE Project
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The advent of inexpensive genome sequencing has opened up malaria research to extensive studies of parasite field isolates as well as to forward genetic methods. However, even with this technological advance, the fact remains that the human malaria parasite genomes remain poorly annotated. This means that finding out what a newly discovered variant does can still take years. The problem is especially acute for genes that could be the targets for next-generation elimination therapies that could prevent malaria or block its transmission. While some important work has already been done to define where parasite genes start and end, under which condition they are transcribed, whether the gene is resistant to disruption, and where the protein goes within the cell, research has been often performed in an uncoordinated and potentially inefficient way. In the human and model organisms communities, researchers have come together to annotate the genome in a systematic way. This ENCODE (encyclopedia of dna elements) project allows interpretation of normal genetic variation in the human genome or pathological variation in cancer cells. The emphasis on lab to lab reproducibility, statistical significance, and standard operating protocols has increased the impact of the project. If data of this type were available for parasites, the search for new therapeutic targets for elimination and eradication would be accelerated.
Targeting Malaria Transmission in an Era of Elimination
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That malaria is persistent in humans despite decades of interventions is testament to the parasite's ability to adapt and transmit efficiently between human and mosquito hosts. Reinvigorated efforts for malaria elimination are now aimed at defining crucial knowledge and tool gaps, with the ultimate goal of efficiently blocking transmission at a population level. One major knowledge gap is our lack of basic understanding of how transmission stage parameters, such as density, circulation time, and the ratios of male to female parasites in human blood, contribute to human infectiousness. Knowing these will enable us to define and quantify infectiousness and also facilitate targeting and evaluate elimination measures. Recent studies suggest a major contribution of asymptomatic carriers to transmission, emphasizing the importance of studying the human infectious reservoir. We have a limited understanding of the mechanisms and targets of protective immunity against transmission stages, particularly those in the human host. Vaccination experiments 40 years ago with transmission stages in chickens demonstrated that humoral transmissionreducing immunity (TRI) can be induced. Since then, both epidemiology studies and mosquito infections with human serum components have demonstrated the existence of natural TRI. However, the specific transmission stage antigens targeted by and threshold responses required for TRI remain to be defined. Upping the momentum for basic and translational research on malaria transmission is needed for the audacious goal of malaria eradication within our lifetime.
Sustaining Success
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Malaria eradication is an important global health success story. Mortality from the mosquito-borne illness has declined 60% since 2000, representing approximately six million lives saved-most of them children. Thanks to unprecedented cooperation from the public, private, and non-profit sectors, malaria deaths-while still too high-are down to a historic low. The standard treatment regimen is artemisinin-based combination therapy (ACT). Along with preventative long-lasting insecticide-treated bed nets, ACT has been a bulwark against the spread of malaria. But we can no longer take these treatments for granted. First documented in Cambodia, artemisinin-resistant malaria has appeared across the populous Mekong Delta region in the past 8 years, and we are now seeing evidence of loss of efficacy of the partner drug. We've had important successes against malaria, but we must guard against complacency. Unless we rapidly confront the spread of drug resistance and redouble efforts to eradicate this disease, we may lose the war. With promising innovative treatment candidates in the pipeline, there's reason for hope. But countries need to withdraw their marketing authorizations for antiquated treatments, including oral artemisinin monotherapies that are key drivers of resistance. The global fight against malaria is succeeding as actors tighten cooperation across sectors and borders. Working together, we believe we can continue to build on these gains and eliminate malaria. Vaccines for malaria have seemed inevitable for decades. In the 60s, IgG from semi-immune African adults was shown to treat blood-stage malaria successfully, and irradiated sporozoites induced sterilizing immunity. Whole-gamete vaccines blocked transmission to mosquitoes in the 70s, and in the 90s we understood that antibodies against placental parasites might protect pregnant women. What happened since? A lot, but we need a better understanding of immunity and the parasite to improve vaccines. In Phase 3 testing, a circumsporozoite protein vaccine reduced clinical malaria in children-the first proven anti-parasite vaccine. However young infants don't respond well, and implementation studies with mortality endpoints await. Irradiated P. falciparum sporozoites can be manufactured and have been shown to prevent infection in some African vaccinees; dose-optimizing studies are ongoing. Other recent firsts: African trials of gamete protein vaccines started; placental malaria vaccines entered human testing. Blood-stage targets of protective antibodies remain unknown, but new proteins implicated in erythrocyte invasion and egress offer promise. What takes so long? Five parasite species cause human malaria, and these parasites infect few other hosts, so we still debate best animal models. Malaria parasites are complex: 5400 genes, immunity and vaccines are stage-specific, and there are numerous lifecycle stages. Systems biology promises to comprehend complexity. All our tools have yielded advances-we need resources commensurate to the problem.
